<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Bart De Strooper</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>KU Leuven<br>UK Dementia Research Institute</td>
</tr>
<tr>
<td class="label">Country</td>
<td>Belgium/UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>180</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-9729-9478" target="_blank">0000-0002-9729-9478</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), Frontotemporal Dementia</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Gamma-secretase](/entities/gamma-secretase), [APP](/entities/app-protein) Processing, [Amyloid](/mechanisms/amyloid-cascade)</td>
</tr>
</table>
Bart De Strooper
Overview
Bart De Strooper is a leading researcher in the field of neurodegenerative diseases, affiliated with KU Leuven and UK Dementia Research Institute. Their research focuses on Gamma-secretase, APP Processing, Amyloid, with particular emphasis on [Alzheimer's Disease](/diseases/alzheimers-disease) and Frontotemporal Dementia. With an h-index of 180, Strooper is among the most cited researchers in the neuroscience field[@orcid2026].
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Bart De Strooper</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>KU Leuven<br>UK Dementia Research Institute</td>
</tr>
<tr>
<td class="label">Country</td>
<td>Belgium/UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>180</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-9729-9478" target="_blank">0000-0002-9729-9478</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), Frontotemporal Dementia</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Gamma-secretase](/entities/gamma-secretase), [APP](/entities/app-protein) Processing, [Amyloid](/mechanisms/amyloid-cascade)</td>
</tr>
</table>
Bart De Strooper
Overview
Bart De Strooper is a leading researcher in the field of neurodegenerative diseases, affiliated with KU Leuven and UK Dementia Research Institute. Their research focuses on Gamma-secretase, APP Processing, Amyloid, with particular emphasis on [Alzheimer's Disease](/diseases/alzheimers-disease) and Frontotemporal Dementia. With an h-index of 180, Strooper is among the most cited researchers in the neuroscience field[@orcid2026].
Strooper's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease and Frontotemporal Dementia. Their research group has made significant contributions to the fields of Gamma-secretase, APP Processing, Amyloid, publishing in high-impact journals including Nature Reviews Neuroscience.
Based at KU Leuven and UK Dementia Research Institute, Strooper collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
Mechanisms of Interest
- Gamma-secretase
- APP Processing
- [Amyloid](/mechanisms/amyloid-cascade)
Programmatic Emphasis
Strooper's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease and Frontotemporal Dementia[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Gamma-secretase, APP Processing, Amyloid domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[Proteases in the pathogenesis of Alzheimer's disease](https://doi.org/10.1038/s41583-018-0058-3). Nature Reviews Neuroscience, 2018.[@proteases2018]
Recent Research
Recent PubMed-indexed publications (2024-2026):
[Phagocytes as plaque catalysts: Human macrophages generate seeding-competent Aβ42 fibrils with cross-seeding activity.](https://pubmed.ncbi.nlm.nih.gov/41770935/). Proceedings of the National Academy of Sciences. 2026 Mar 10.
[Aβ plaques induce local pre-synaptic toxicity in human iPSC-derived neuron xenografts.](https://pubmed.ncbi.nlm.nih.gov/41483813/). Stem Cell Reports. 2026 Jan 13.
[The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia.](https://pubmed.ncbi.nlm.nih.gov/41286448/). Nature Neuroscience. 2026 Jan.
[Bioenergetics and lipid metabolism in Alzheimer's disease: From cell biology to systemic health.](https://pubmed.ncbi.nlm.nih.gov/41198597/). Journal of Internal Medicine. 2026 Jan.
[The Curious Case of a Heterozygous Loss-of-Function PSEN1 variant associated with Early-Onset Alzheimer's Disease.](https://pubmed.ncbi.nlm.nih.gov/40909785/). Research square. 2025.
[Divergent Effects of APOE3 and APOE4 Human Astrocytes on Key Alzheimer's Disease Hallmarks in Chimeric Mice.](https://pubmed.ncbi.nlm.nih.gov/39975251/). bioRxiv. 2025.
Collaborators and Research Network
Collaborator network pending enrichment.
Institutional Context
Primary institutional links: [KU Leuven](/institutions/ku-leuven), [UK Dementia Research Institute](/institutions/uk-dementia-research-institute). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Gamma-secretase, APP Processing, Amyloid signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Frontotemporal Dementia into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0002-9729-9478](https://orcid.org/0000-0002-9729-9478)
- Google Scholar: [Search for Bart De Strooper](https://scholar.google.com/scholar?q=author%3A%22Bart+De+Strooper%22)
- PubMed: [Author search for Bart De Strooper](https://pubmed.ncbi.nlm.nih.gov/?term=Bart+De+Strooper%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
Recent Publications
Recent Publications
[Phagocytes as plaque catalysts: Human macrophages generate seeding-competent Aβ40/42](https://pubmed.ncbi.nlm.nih.gov/41770935/). Proc Natl Acad Sci U S A. 2026 Mar 10.
[The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-specific antibody response](https://pubmed.ncbi.nlm.nih.gov/41286448/). Nat Neurosci. 2026 Jan.
[Bioenergetics and lipid metabolism in Alzheimer's disease: From cell biology to translation](https://pubmed.ncbi.nlm.nih.gov/41198597/). J Intern Med. 2026 Jan.
[The APOE isoforms differentially shape the transcriptomic and epigenomic landscape of microglia](https://pubmed.ncbi.nlm.nih.gov/40419479/). Nat Commun. 2025 May 27.
[Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease pathology](https://pubmed.ncbi.nlm.nih.gov/40237235/). Alzheimers Dement. 2025 Apr.Research Contributions
Mermaid diagram (expand to render)
References
[Unknown, Proteases in the pathogenesis of Alzheimer's disease (2018)](https://doi.org/10.1038/s41583-018-0058-3)
Unknown, ORCID profile for Bart De Strooper (2026)
[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)